GlassScriptPhysician profile
Hafsa Farooq
NPI 1942651393
$3,252.77
in general payments reported to CMS, 2019-2025
45 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $444 · 2023: $22.07 · 2024: $1,732 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.86 |
| Education | $263.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $335.45 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $285.29 | 2022-2025 | Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $219.94 | 2024-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $202.91 | 2024-2025 | |
| Janssen Biotech, INC. | $193.29 | 2022-2025 | Darzalex, Rybrevant, Tecvayli |
| Merck Sharp & Dohme LLC | $156.45 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $132.05 | 2024 | Jakafi |
| Genzyme Corporation | $108.24 | 2024-2025 | |
| Genentech USA, INC. | $107.63 | 2021 | |
| Pfizer INC. | $97.31 | 2024-2025 | |
| Array Biopharma INC | $96.77 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Cumberland Pharmaceuticals, INC. | $93.47 | 2024-2025 | Sancuso |
| Glaxosmithkline, LLC. | $88.01 | 2025 | Ojjaara |
| Regeneron Healthcare Solutions, INC. | $83.91 | 2024 | Libtayo |
| Celgene Corporation | $79.48 | 2024-2025 | Reblozyl |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $77.64 | 2024-2025 | Enhertu, Injectafer |
| Seagen INC. | $73.99 | 2022 | |
| Rigel Pharmaceuticals, INC. | $59.41 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Sobi, INC | $45.93 | 2024 | |
| Pharmaessentia USA Corporation | $45.06 | 2024 | Besremi |
| Taiho Oncology, INC. | $37.62 | 2024 | |
| Alexion Pharmaceuticals, INC. | $37.21 | 2024 | Ultomiris |
| Beigene USA, INC. | $36.86 | 2024-2025 | Brukinsa |
| Beone Medicines USA, INC. | $36.35 | 2025 | Brukinsa |
| Abbvie INC. | $36.11 | 2025 | |
| Lilly USA, LLC | $33.87 | 2024 | Verzenio, Jaypirca |
| Eisai INC. | $33.79 | 2024-2025 | |
| Coherus Oncology, INC. | $33.31 | 2024 | |
| Servier Pharmaceuticals LLC | $31.66 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $30.62 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.21 | 2024 | Fruzaqla, Ninlaro |
| Karyopharm Therapeutics INC. | $29.31 | 2024 | Xpovio |
| Exelixis INC. | $28.51 | 2024 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $28.43 | 2024 | |
| Myriad Genetic Laboratories, INC. | $27.42 | 2024 | Myrisk |
| Adaptive Biotechnologies Corporation | $26.39 | 2024 | Clonoseq |
| Blueprint Medicines Corporation | $22.18 | 2024 | Ayvakit |
| Tempus Ai, INC | $19.81 | 2024 | |
| Invivyd INC | $17.56 | 2025 | Pemgarda |
| Puma Biotechnology, INC. | $16.86 | 2024 | |
| Geron Corporation | $16.46 | 2025 | Rytelo |
| Kyowa Kirin, INC. | $16.02 | 2024 | Poteligeo |
| Biocon Biologics INC | $15.44 | 2024 | Ogivri |
| Springworks Therapeutics, INC. | $15.05 | 2024 | Ogsiveo |
| Stemline Therapeutics INC. | $13.49 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hafsa Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.